A question of capacity
Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more
The RCN has recommended it to members, and believes it is acceptable if government predictions of falling inflation prove correct. Unite has rejected it outright, and Unison is consulting its members.
Inflation as measured by the retail price index (RPI), which includes factors such as house prices, is currently running at 3.8 per cent.
The government says this will fall to 3 per cent by the end of the year, and further thereafter.
RCN head of employment relations Josie Irwin told Independent Nurse that the union would activate a clause to reopen pay talks if government predictions proved even fractionally inaccurate. 'If the RPI was 3.2 per cent at Christmas and looked like staying still, we would go to the Pay Review Body.' She said this could apply even at 3.1 per cent.
The review body would then seek a remit from ministers to revise the pay deal, she said.
Ms Irwin said if inflation was 3 per cent in the second or third years of the pay deal, 'of course' the clause would be activated. This could happen with inflation at 2.5 per cent if other factors such as increased levels of nurse emigration demanded it, she said.
Asked to guarantee that the DoH would honour the inflation clause, health secretary Alan Johnson told the RCN Congress in Bournemouth last week that there was 'no force on earth' that would stop the deal being reworked if inflation demanded it.
Comment below and tell us what you think.
Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more
The WPBA should be seen as a developmental process, says the RCGP's Dr Jane Mamelok. Read more
Working as an educational supervisor can be stimulating and rewarding, says Dr Alexander Williams. Read more
Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more
Contributed by Dr David Kernick, a GPSI in headache, based in Exeter. Read more
Section 1: Epidemiology and aetiology Read more
Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more
The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more
Comments
Only registered users may comment. Log in now or register for a free account.